Rarer Cancers Forum

LONDON, February 26, 2010 - NICE will convene today after two years of delays, to exercise their final opportunity to reverse the fate of thousands of UK advanced primary liver cancer patients who were told in November that they will be denied their only survival option, Nexavar(R) (sorafenib) on the NHS.